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https://doi.org/10.1016/j.stemcr.2017.09.004SUMMARYThe FUS gene has been linked to amyotrophic lateral sclerosis (ALS). FUS is a ubiquitous RNA-binding protein, and themechanisms lead-
ing to selective motoneuron loss downstream of ALS-linked mutations are largely unknown. We report the transcriptome analysis of
human purified motoneurons, obtained from FUS wild-type or mutant isogenic induced pluripotent stem cells (iPSCs). Gene ontology
analysis of differentially expressed genes identified significant enrichment of pathways previously associated to sporadic ALS and other
neurological diseases. Several microRNAs (miRNAs) were also deregulated in FUSmutant motoneurons, including miR-375, involved in
motoneuron survival. We report that relevant targets of miR-375, including the neural RNA-binding protein ELAVL4 and apoptotic fac-
tors, are aberrantly increased in FUSmutant motoneurons. Characterization of transcriptome changes in the cell type primarily affected
by the disease contributes to the definition of the pathogenic mechanisms of FUS-linked ALS.INTRODUCTION
The fatal neurodegenerative disease amyotrophic lateral
sclerosis (ALS) is caused by loss of motoneurons (MNs) in
the spinal cord and brain, leading to progressive muscle
atrophy. Both sporadic ALS (sALS) and familial ALS (fALS)
have been linked to a number of genes, including SOD1,
C9ORF72, TDP-43, TAF15, and FUS/TLS (FUS) (Renton
et al., 2014). The FUS gene encodes for an RNA-binding pro-
tein involved in RNA biogenesis and maturation (Lagier-
Tourenne et al., 2012). Wild-type (WT) FUS is mainly local-
ized in the nucleus, and a hallmark of FUS ALS patients is
the presence of cytoplasmic inclusions containingmutated
protein in the brain and spinal cord (Kwiatkowski et al.,
2009; Vance et al., 2009). Many ALS-associated FUS muta-
tions disrupt the function of the C-terminal nuclear locali-
zation signal (NLS). Therefore, defects in nuclear import,
leading to aberrant cytoplasmic localization of FUS, have
been proposed as the initial step in ALS pathogenesis (Bent-
mann et al., 2013; Dormann and Haass, 2011). Recent an-
alyses in murine models suggest that loss of FUS function
may not be sufficient to induce MN degeneration (Kino
et al., 2015; Scekic-Zahirovic et al., 2016), and both loss
of a nuclear function and gain of a toxic function in the
cytoplasm have been proposed as contributing patholog-
ical mechanisms in FUS ALS (Ling et al., 2013).
FUS mutations are expected to exert a major change in
the transcriptome. However, this has not been directly ad-
dressed in human MNs so far. Human induced pluripotent
stem cells (iPSCs) represent a useful system tomodel ALS, as
they can be differentiated into disease-relevant cell typesStem Ce
This is an open access article under the C(Sances et al., 2016). iPSCs carrying ALS mutations can
be generated by reprogramming from patients (Boulting
et al., 2011) or by gene-editing techniques, producing lines
that differ only for the specific mutation (Kiskinis et al.,
2014; Lenzi et al., 2015). Comparison of gene-edited
mutant lines with their otherwise isogenic WT counter-
parts allows to assign any observed phenotypic difference
to the ALS mutation, avoiding any bias due to different ge-
netic backgrounds of non-isogenic mutants and controls.
Recent evidence suggests that microRNAs (miRNAs)
might play a role in MN diseases, such as ALS and spinal
muscular atrophy (SMA) (Kye and Gonc¸alves, 2014). Con-
ditional loss of the processing enzyme Dicer in postnatal
MNs causes an SMA-like phenotype in mice (Haramati
et al., 2010), suggesting that, collectively, miRNAs could
be required for MN survival. Global downregulation of
miRNAs was observed in MNs of sporadic ALS spinal cords
isolated by laser-capture microdissection (Emde et al.,
2015), and a protective role for individual miRNAs, such
as miR-218 and miR-375, has been shown in MNs (Amin
et al., 2015; Bhinge et al., 2016). Previous work from our
lab and others has shown that proteins genetically linked
to ALS play a role in miRNA biogenesis. FUS stimulates
miRNA processing by facilitating the recruitment of the
enzyme Drosha on miRNA genes (Morlando et al., 2012),
and TDP-43 regulates miRNA biogenesis at multiple levels
(Buratti et al., 2010; Di Carlo et al., 2013; Kawahara and
Mieda-Sato, 2012). Moreover, overexpression of SOD1,
TDP-43, or FUS proteins, either WT or carrying ALS muta-
tions, impaired miRNA processing in the cytoplasm by
inducing cellular stress (Emde et al., 2015). As most of thell Reports j Vol. 9 j 1–13 j November 14, 2017 j ª 2017 The Author(s). 1
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biogenesis come from cell lines or non-MN cells, it is
currently unknown which miRNAs could be affected by
ALS mutations in MNs.
Here we took advantage of mutant FUSP525L and isogenic
control iPSCs to generate and isolate pure human MNs,
which were used for whole-transcriptome analysis by
RNA sequencing (RNA-seq). We identified both long and
short RNA species significantly altered in FUS mutant
MNs. Changes in the transcriptome point to pathways
previously associated to neurodegenerative diseases, such
as those related to cell adhesion. Among differentially
expressed miRNAs we focused on miR-375. Levels of miR-
375 were decreased in mutant MNs, in which we observed
an increase of a subset of its targets, such as p53 and the
neural RNA-binding protein ELAVL4. We propose a patho-
logical mechanism in which an impairment of miRNAs
production, downstream of FUS mutations, would alter
RNA metabolism and increase MN vulnerability via aber-
rant upregulation of pro-apoptotic targets.RESULTS
Differentiation and Isolation of iPSC-Derived MNs
We have recently reported the generation of iPSC lines
devoid of mutations in the FUS gene (hereafter FUSWT) or
carrying the severe P525L ALS-relatedmutation introduced
by gene editing in both FUS alleles (hereafter FUSP525L)
(Lenzi et al., 2015).We stablymodified these lines by insert-
ing aHb9:GFP reporter into theAAVS1 locus (Wainger et al.,
2014) (Figures S1AandS1B). To improve timeandefficiency
ofMNgeneration from iPSCs,we took advantage of anopti-
mized protocol based on neural induction and patterning
of differentiating cells in adhesion conditions (Figure 1A).
Using this protocol we consistently obtained MN progeni-
tors in a 12 day time frame. A time course analysis ofmarker
expression in differentiating FUSWT cells is shown in Fig-
ure 1B. By day 6, cells lose the pluripotencymarkerNANOG.
Around this time point we detected a peak of expression for
the neural progenitor gene PAX6, followed by a raise of pan-
neuronal (TUJ1) and MN (ISL1) markers at day 9. The late
MN gene CHAT was expressed at day 9, with a further in-
crease until day 12. Levels of the MN progenitor marker
HB9peaked aroundday9 anddecreased at later timepoints.
The mixed population of differentiated cells at day 12 was
highly enriched of ISL1/2-positive neurons (Figure S1C).
Live cell imaging and flow cytometry analysis indicated
that 30%–40% of cells were GFP-positive at this time point
(Figures 1Cand1D).Notably, expressionof the reporterwas
detected only in retinoic acid and smoothened agonist
(SAG)-treated cells, which induce a ventral spinal cord
character, suggesting that the exogenous Hb9 promoter2 Stem Cell Reports j Vol. 9 j 1–13 j November 14, 2017was correctly turned on in the MN lineage (Figure 1E). We
further validated the reporter system by gene expression
analysis in distinct cell populations isolated using cell sort-
ing (Figure S1D). Next-generation sequencing (RNA-seq)
was performed on total RNA from GFP-positive and -nega-
tive cells collected after sorting. Cluster analysis based on
gene expression data correctly separated the samples into
GFP-positive and -negative ones (Figures S1E and S1F).
GFP-positive samples had a similar expressionprofile,while
GFP-negative ones were more dissimilar. A total of 1,631
genes were differentially expressed between GFP-positive
and -negative cells, most of them having higher expression
levels in GFP-negative samples (Figure S1G; Table S1). As
shown in Figure 1F, levels of MN markers (in green) were
higher in GFP-positive samples, with the exception of
LHX1. Notably, theHB9 transcript was not significantly en-
riched in GFP-positive samples. This apparent inconsis-
tency can be explained by the narrow window of time of
HB9 expression: by the time point in which GFP protein
reaches its maximum accumulation (day 12; Figure 1D)
the endogenous HB9mRNA is already downregulated (Fig-
ure 1B). Compared with GFP-positive cells, GFP-negative
populations probably contained a fraction of MN progeni-
tors at earlier stages, expressing high levels of HB9. As
expected, ALS-related genes SOD1, C9ORF72, FUS, and
TARDBP were not enriched in GFP-positive cells. Experi-
mental validation of selected markers by real-time qPCR
confirmed the RNA-seq results (Figure 1G). Purified GFP-
positive cells were re-plated on laminin-coated dishes and
upon further culturing acquired a neuronal morphology
(Figure S1H). Immunostaining analysis indicated that
sorted GFP-positive cells were highly enriched for ISL1/2-
positive MNs (Figure 1H).
Taken together, the combination of a short and efficient
differentiation protocol and the stable insertion of the
Hb9:GFP reporter allowed the effective isolation of a large
number of purified, iPSC-derived, MNs.
Transcriptome Profiling in FUS WT and Mutant
Human MNs
We have previously shown that ALS mutations in FUS do
not impair differentiation (Lenzi et al., 2015, 2016). This
observation was confirmed in MNs generated with the
improved protocol described in Figure 1 from FUSWT and
FUSP525L iPSCs. The fraction of GFP-positive cells was
consistently comparable over six independent experi-
ments (Figures 2A and 2B). Moreover, GFP-positive cells
with a FUSWT or FUSP525L background showed comparable
levels of expression ofMNmarkers (Figure S2A). Notably, in
the Hb9:GFP FUSP525L line both the mutation and the
reporter system have been introduced by gene editing.
Therefore, besides the FUSP525L mutation, iPSC lines used
for subsequent experiments were isogenic.
Figure 1. MN Differentiation Protocol
and Hb9:GFP Reporter
(A) Schematic representation of the differ-
entiation protocol.
(B) Real-time qRT-PCR marker expression
analysis. For each marker the time point
with the highest expression has been used
as the calibrator sample.
(C) Live cell imaging of GFP expression in
differentiated cells at day 12. Scale bar,
80 mm.
(D) Schematic representation of flow cy-
tometry analysis of the fraction of GFP-
positive cells during differentiation.
(E) Cells were differentiated as in (A) in the
presence (right) or in the absence (left) of
retinoic acid and SAG, and analyzed by
fluorescence-activated cell sorting (FACS)
at day 12.
(F) Heatmap representing expression levels
of selected genes in sorted GFP-positive
and -negative cells (two independent ex-
periments). Plotted values correspond to
mean-centered log2-transformed reads per
kilobase of transcript per million mapped
reads (RPKM) values. MN markers are
indicated in green, ALS genes in red, and
housekeeping controls in black.
(G) Real-time qRT-PCR analysis of the
expression of the indicated genes in un-
sorted cells (black bars) and GFP-negative
(gray bars) and GFP-positive (green bars)
cells isolated by FACS (day 12). For each
gene the unsorted cells sample has been
used as calibrator. Histogram bars represent
the average of a technical replicate (n = 3)
and error bars indicate the SD.
(H) Immunostaining analysis of sorted MNs
(day 12 + 3) with an anti-ISL1/2 antibody
(green). Nuclei were stained with DAPI
(blue). Upper panels show single channels.
Lower panels show merged channels and
overlay with the phase contrast image. Scale
bar, 40 mm. See also Figure S1.
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analyze the consequences of the FUSP525L mutation on
the transcriptome in pure populations of in-vitro-derived
human MNs. GFP-positive FUSWT and FUSP525L iPSCs
were sorted at day 12 of differentiation and further cultured
on laminin-coated dishes for an additional 7 days (day
12 + 7). Total RNA from three independent differentiation
experiments was collected and analyzed by RNA-seq. Gene
expression-based cluster analysis resulted in the segrega-
tion of samples into two distinct groups based on their
FUS genotype (Figures S2B and S2C). Out of 14,289 genesexpressed in human MNs, 267 genes were upregulated
and 244 downregulated in a consistentmanner in FUSP525L
compared with FUSWT (false discovery rate [FDR] < 0.05)
(Table S1). The gene expression heatmap of differentially
expressed genes is shown in Figure 2C. RNA-seq results
were validated by real-time qPCR in at least three addi-
tional independent samples. Figure 2D shows validation
of four representative genes among those downregulated
(SCL17A8, NXPH2, CRIM1, and GRIN2A) and upregulated
(TP53I3, CDH7, NNAT, and TSPYL5). Expression of the
FUS transcript itself, as well as the mRNAs of other majorStem Cell Reports j Vol. 9 j 1–13 j November 14, 2017 3
Figure 2. RNA-Seq Analysis of FUSWT and FUSP525L iPSC-Derived MNs
(A) Representative FACS plots of FUSWT and FUSP525L cells at day 12. As a negative control, FUSWT cells were differentiated in the absence of
retinoic acid and SAG (left panel).
(B) Schematic representation of flow cytometry analysis (day 12). Histogram bars represent the average of six independent experiments
and error bars indicate the SD (Student’s t test; unpaired; two tails; n.s., p > 0.05).
(legend continued on next page)
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mutant MNs (Figure S2D).
We confirmed these results in an independent FUS WT
and mutant isogenic pair. A second FUSP525L iPSC line
(hereafter FUSP525L#2), generated as previously described
(Lenzi et al., 2015), and its parental FUSWT iPSC line (here-
after FUSWT#2) were modified by inserting the Hb9:GFP re-
porter into the AAVS1 locus (Figures S3A–S3D). FUSWT#2
and FUSP525L#2 were then differentiated, sorted, and
collected at day 12 + 7 for RNA analysis. All genes analyzed
in the original isogenic pair resulted consistently altered in
MNs obtained from these new iPSC lines (Figure 2D).
A subset of these genes was also affected inMNs obtained
from aHb9:GFP-modified heterozygous FUSP525L iPSC line,
hereafter FUSP525L(ht) (Lenzi et al., 2015) (Figure 2D).
Functional Consequences of the FUSP525L Mutation in
Human MNs
We next assessed whether the change in the transcriptome
detected in FUSmutant cells might be informative of path-
ways potentially involved in ALS MN degeneration. Gene
ontology (GO) term enrichment analysis with the FIDEA
tool (D’Andrea et al., 2013) highlighted relevant categories
that cooperate in pathways and distinct molecular func-
tions. In particular, we noticed a striking enrichment for
categories related to cell adhesion in genes differentially
expressed in FUSP525L MNs (Figure 3A). Notably, ‘‘cell adhe-
sion’’ is one of the categories consistently enriched in mul-
tiple studies focusing on FUS-bound transcripts and splice
targets in mouse and human neurons (Orozco and Edba-
uer, 2013). GO term enrichment analysis of differentially
expressed genes in laser-captured MNs from postmortem
sporadic ALS patients also indicated ‘‘cell adhesion’’ (Batra
et al., 2016). Moreover, functional enrichment analysis for
genome-wide association studies involving several neuro-
logical diseases (including ALS) showed significant values
for the ‘‘cell-cell adhesion’’ GO category (Guio-Vega and
Forero, 2017). This category was also enriched in the anal-
ysis of differentially expressed genes in ALS fibroblasts
carrying the C9ORF72 mutation (Kotni et al., 2016). Cell
adhesion-related categories were enriched also when upre-
gulated and downregulated genes were analyzed separately
(Figure S4A). Interestingly, the Kyoto Enrichment of Genes
and Genomes pathway ‘‘Neuroactive ligand-receptor inter-
action’’ was specifically enriched by the downregulated
genes. Previous work found this pathway enriched in(C) Heatmap representing RNA-seq-derived expression levels of diffe
ments). Plotted values correspond to mean-centered log2-transforme
(D) Validation of selected genes by real-time qRT-PCR in MNs at day 12
shown as relative to their respective isogenic FUSWT controls, set to a
independent experiments and error bars indicate the SD (Student’s t
p > 0.05). See also Figures S2 and S3.RNA profiling from C9ORF72 mutant fibroblasts (Kotni
et al., 2016) and linked to neurological diseases such as
Parkinson’s disease (Kong et al., 2015).
Seeking for ALS signature in FUSmutantMNs, we crossed
our RNA-seq data with a recently published dataset from
laser-captured MNs fom sALS patients (Batra et al., 2016;
Kapeli et al., 2016). In these works, the authors found
2,346 upregulated and 955 downregulated genes in sALS
patients. The variation of upregulated genes was more
robust, since more stringent selection criteria had lower
impact on their abundance. These two lists of genes were
employed as two distinct gene sets in the context of a
gene set enrichment analysis to evaluate whether they
were over-represented in the set of genes deregulated
upon FUS mutation. Notably, the set of genes downregu-
lated in sALS patients was enriched among those downre-
gulated in FUSP525L (FDR = 0.151), and the set of genes
upregulated in sALS patients was significantly enriched
among those upregulated in FUSP525L (FDR = 0.009) (Fig-
ure S4B). These results suggest a common signature in
gene expression between in-vitro-derived FUSP525L MNs
and sALS MNs. As suggested by FDR values, this tendency
is stronger for the upregulated genes, consistent with the
robustness of their deregulation in sALS patients.
We next investigated whether there is any relationship
between differential gene expression and direct FUS bind-
ing in mutant MNs. The FUS interactome has never been
characterized in purified human MNs; however, FUS
CLIP-seq (crosslinking and immunoprecipitation, followed
by high-throughput sequencing) data from human brain
cortex are available (Lagier-Tourenne et al., 2012). We re-
analyzed this dataset and evaluated the position of FUS
binding clusters relative to the different regions of the
pre-mRNAs, which are expressed in our MNs. FUS binding
was enriched in the exonic regions of protein-coding
genes, and in particular in the 30 UTR, when compared
with sequences located more (distal introns) or less (prox-
imal introns) than 500 bp from the nearest exon-intron
junction (Figure 3B). FUS-bound genes were classified as
differentially expressed or not in FUSP525L MNs, and indi-
vidual mRNA regions were analyzed separately. A signifi-
cantly higher percentage of genes modulated in FUS
mutantMNs was directly bound by FUS in the distal intron
and 30 UTR (Figure 3C). When the same analysis was
repeated with the TDP-43-bound genes dataset (Tollervey
et al., 2011), we did not observe a significant enrichmentrentially expressed genes at day 12 + 7 (three independent experi-
d RPKM values.
+ 7. Expression levels in FUSP525L, FUSP525L#2, and FUSP525L(ht) are
value of 1. Histogram bars represent the average of at least three
test; paired; two tails; *p < 0.05; **p < 0.01; ***p < 0.001; n.s.,
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Figure 3. Bioinformatics Analysis of Differentially Expressed Genes in FUSWT and FUSP525L MNs
(A) Word cloud generated by FIDEA representing GO biological process terms enriched in the list of genes that are differentially expressed
between FUSWT and FUSP525L MNs. The functional categories are represented with a character size proportional to the statistical signifi-
cance of their enrichment.
(B) The histogram shows the fold enrichment of FUS binding sites, identified by re-analysis of data from Lagier-Tourenne et al. (2012), in
different regions of pre-mRNAs, after normalization to average region size.
(C) Fraction of FUS bound protein-coding genes, which are also differentially expressed genes in FUS mutant MNs. A gene was considered
bound if a FUS HITS-CLIP peak was found within its body; the analysis was repeated focusing only on specific pre-mRNA regions (Fisher’s
exact test; *p < 0.05; ***p < 0.001).
(D) Validation of selected FUS-bound genes in MNs at day 12 + 7 by real-time qRT-PCR. Expression levels in FUSP525L, FUSP525L#2, and
FUSP525L(ht) are shown as relative to their respective isogenic FUSWT controls, set to a value of 1. Histogram bars represent the average
of at least three independent experiments and error bars indicate the SD (Student’s t test; paired; two tails; *p < 0.05; **p < 0.01;
***p < 0.001; n.s., p > 0.05).
(E) Venn diagram showing the overlap between differentially expressed genes in the present work and in a FUS mutant mouse (Scekic-
Zahirovic et al., 2016). See also Figure S4.
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suggest that mRNAs bound by FUS in the 30 UTR might be
more susceptible to changes in FUS activity due to ALS
mutations. We validated differential expression of selected6 Stem Cell Reports j Vol. 9 j 1–13 j November 14, 2017FUS-boundmRNAs inmutantMNs (TAF7, TAF15,GRIN2A,
PCDH10, and CRIM1) (Figures 2D and 3D).
To assess whether the changes in gene expression down-
stream of FUS ALSmutations are consistent with an animal
Figure 4. miR-375 Is Downregulated in FUS Mutant MNs
(A) Venn diagram showing the relations between differentially expressed miRNAs at different time points of MN maturation, as resulting
from TaqMan array cards analysis in FUSWT and FUSP525L iPSC-derived MNs at day 12 and 12 + 7, and small RNA-seq at day 12 + 7 (p < 0.05).
(B) Validation of selected miRNAs by real-time qRT-PCR in MNs at day 12 + 7. Expression levels in FUSP525L and FUSP525L#2 are shown as
relative to their respective isogenic FUSWT controls, set to a value of 1. Histogram bars represent the average of at least four independent
experiments and error bars indicate the SD (Student’s t test; paired; two tails; *p < 0.05; ***p < 0.001; n.s., p > 0.05).
(C) Real-time qRT-PCR analysis of the indicated miRNAs in FUSWT undifferentiated iPSCs and MNs (day 12 of differentiation, unsorted).
miR-302a and miR-367 are pluripotency miRNAs; miR-218 is an MN-enriched miRNA. For each miRNA, the sample with the highest
(legend continued on next page)
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the transcriptome profiling of a recently described mouse
carrying targeted deletion of the PY-NLS (FusDNLS/DNLS)
(Scekic-Zahirovic et al., 2016). This mutation severely im-
pairs the nuclear localization of FUS, mimicking the hu-
man P525L mutation and other truncations of the protein
C-terminal. Among differentially expressed genes, 17 were
downregulated and 8 were upregulated in both mutant
mouse brain and human MNs (Figures 3E and S4D). The
overlap was statistically significant both for upregulated
and downregulated gene lists (p value for hypergeometric
test <0.05). Interestingly, mRNA levels of TAF15, a FUS fam-
ilymembermutated in a subset of fALS patients (Couthouis
et al., 2011), were significantly increased in both mouse
(Scekic-Zahirovic et al., 2016) and human (Figure 3D).
TAF15 was among the transcripts directly bound by FUS
(Lagier-Tourenne et al., 2012). These findings suggest that
a possible crosstalk between FUS and TAF15, hypothesized
in murine models, might be conserved in human.
FUSP525LMutation ImpairsmiR-375 Biogenesis inMNs
by a Loss-of-Function Mechanism
Previous studies in cell lines have hypothesized a link
between FUS mutations and the impairment of miRNA
function (Emde et al., 2015; Morlando et al., 2012), but
this was never directly investigated in humanMNs.We per-
formed miRNA profiling by small RNA sequencing (small
RNA-seq) in FUSWT and FUSP525L MNs. Based on miRNA
expression levels, samples could be clustered according to
their FUS genotype (Figures S5A–S5C). Of the 573 miRNAs
expressed in human MNs (day 12 + 7), 21 resulted downre-
gulated and 11 upregulated in FUSP525L mutant cells (FDR <
0.05) (Figure S5D; Table S1). We also analyzed to which
extent the change in the miRNome is maintained at
different time points. TaqMan array cards and small
RNA-seq identified miR-375 and miR-484 as differentially
expressedmiRNAs at both day 12 and day 12 + 7 (Figure 4A;
Table S2). These and other selected candidates were
analyzed by real-time qRT-PCR in FUSP525L, FUSP525L#2,
and FUSP525L(ht) MNs, and their isogenic WT controls (Fig-
ures 4B, S5E, and S5F). Among them, miR-375 was consis-
tently downregulated in both homozygous FUS mutant
lines over at least four independent experiments (Figure 4B).
miR-375 has been recently described as a protective
miRNA inMNs (Bhinge et al., 2016). Consistent with previ-
ous observations (Bhinge et al., 2016), miR-375 was highly
upregulated in MNs compared with undifferentiated iPSCsexpression has been used as the calibrator. Histogram bars represent
the SD.
(D) Real-time qRT-PCR analysis in differentiated FUSWT iPSCs (day
represent the expression relative to the siRNA control (average of thr
t test; paired; two tails; *p < 0.05; **p < 0.01; where not indicated p
8 Stem Cell Reports j Vol. 9 j 1–13 j November 14, 2017(Figure 4C). To gain insights into themechanisms underly-
ing miR-375 downregulation in FUSP525L MNs we trans-
fected differentiating FUSWT iPSCs with small interfering
RNAs (siRNAs) targeting FUS and analyzed gene expression
at day 12 of differentiation. In these conditions, FUS levels
were reduced to about 60% compared with scramble
siRNA-transfected cells (Figure 4D). We have previously
shown that FUS localization in the nucleus in homozygous
FUSP525L cells is reduced to 50% of its normal levels, due to
partial delocalization in the cytoplasm (Lenzi et al., 2015).
Therefore, the decrease of FUS achieved by siRNA in WT
cells is expected to reproduce possible loss of nuclear func-
tion effects of the mutation. FUS reduction did not affect
differentiation, as assessed by ISL1,CHAT, and TUJ1marker
analysis (Figure 4D). Levels of miR-375 were significantly
reduced upon FUS knockdown (Figure 4D). Conversely,
expression of selected genes among the most upregulated
(NNAT, TSPYL5, and TAF15) or downregulated (CRIM1
and SLC17A8) ones in FUSP525L MNs was not affected by
FUS knockdown (Figure 4D).
These results suggest that ALS mutations in the FUS gene
might impair miR-375 production via a nuclear loss-of-
function mechanism, while gain of toxic functions of the
mutated protein might underlie the alteration of protein-
coding genes expression.
miR-375 Target Genes in FUSMutant MNs
To identify miR-375 targets in human MNs, we crossed
mRNA expression data from the RNA-seq with predicted
(TargetScan; Agarwal et al., 2015) and previously validated
targets (miRTarBase; Chou et al., 2016). Eight mRNAs upre-
gulated in FUSP525L MNs were also miR-375 predicted tar-
gets (Figure 5A; Table S3), including ELAVL4 (also known
as HuD), which had been previously validated as a bona
fide miR-375 target (Abdelmohsen et al., 2010). The
increased expression of ELAVL4 and other predicted targets
(PHLDA1, EBF3, B3GAT2) in mutant MNs was validated by
real-time qPCR (Figure 5B). The ELAVL4 gene encodes for a
neuron-specific RNA-binding protein (Bronicki and Jas-
min, 2013). In mouse MNs, the transcript of the NRN1
(CPG15) gene is among known targets of ELAVL4, which
promotes NRN1 mRNA accumulation by enhancing its
stability (Akten et al., 2011). In line with this, we detected
increased levels of NRN1 in FUSP525L MNs (Figure 5B).
We then noticed that the p53 gene (TP53) was a
previously described target of miR-375 (Liu et al., 2013).
TP53 mRNA was unchanged or slightly upregulated,the average of a technical replicate (n = 3) and error bars indicate
12) transfected with anti-FUS or control siRNAs. Histogram bars
ee independent experiments). Error bars indicate the SD (Student’s
> 0.05). See also Figure S5.
Figure 5. miR-375 Target Analysis
(A) Venn diagram showing the relations between predicted miR-375 targets and mRNAs upregulated in FUSP525L MNs, as resulting from the
RNA-seq analysis.
(B) Real-time qRT-PCR analysis in MNs at day 12 + 7. Expression levels in FUSP525L and FUSP525L#2 are shown as relative to their respective
isogenic FUSWT controls, set to a value of 1. Histogram bars represent the average of at least three independent experiments and error bars
indicate the SD (Student’s t test; paired; two tails; *p < 0.05; ***p < 0.001; n.s., p > 0.05).
(C) Western blot analysis of p53 protein levels in FUS wild-type and mutant MNs at day 12 + 7. GAPDH is used as a housekeeping control.
(D) Real-time qRT-PCR analysis of the expression of the indicated genes in differentiated FUSP525L iPSCs transfected with miR-375 miRNA
mimics. Expression levels are relative to mimics control (mimics-C)-transfected samples. Histogram bars represent the average of at least
three independent experiments and error bars indicate the SD (Student’s t test; paired; two tails; *p < 0.05; ***p < 0.001; n.s., p > 0.05).
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In both lines, we detected an increase of p53 protein by
western blot (Figure 5C). Among miR-375 targets, we
noticed that EBF3 and PHLDA1 (also known as TDAG51)
have been previously involved in the induction of
apoptosis (Gomes et al., 1999; Zhao et al., 2006).
To assess whether changes in targetmRNA levels could be
explained by differences in miRNA levels, we transfected
synthetic miR-375 mimics in FUSP525L differentiated cells.
We observed a significant decrease of ELAVL4 and TP53
mRNA levels compared with control-transfected cells
(mimics-C) (Figure 5D). Since levels of EBF3 and PHLDA1
were not decreased, we hypothesize that other mecha-
nisms might contribute to their upregulation in FUS
mutant cells.
Collectively, these findings suggest that dysregulation
of miR-375 in FUS mutant MNs may have an impact on
RNA metabolism and survival due to aberrant increase of
ELAVL4 and p53, respectively.DISCUSSION
In this study we report the whole-transcriptome profile of
in-vitro-derived human MNs with WT or mutant (P525L)
FUS background. Our analysis was performed on two pairs
of isogenic lines generated by gene editing. We therefore
provide significant information on the changes in the tran-
scriptome of the neuronal subtype primarily affected by
ALS and due solely to the specific, ALS-linked, FUSP525Lmu-
tation. This represents a major advance beyond previous
work, in which the transcriptome of mixed populations
of progenitor cells (composed for the most part of non-
MN cells and derived from non-isogenic FUS control/
mutant iPSCs) was profiled by exon array (Ichiyanagi
et al., 2016).
We found that numerous differentially expressed genes
belong to functional categories related to the cell adhesion
pathway. Interestingly, this correlates with transcriptome
analysis of postmortem laser-capture microdissected MNsStem Cell Reports j Vol. 9 j 1–13 j November 14, 2017 9
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several neurological diseases and differential gene expres-
sion in C9ORF72 mutant cells (Aronica et al., 2015; Batra
et al., 2016; Guio-Vega and Forero, 2017; Kotni et al.,
2016). In the light of our findings, cell adhesion-related
pathways might be considered as biomarkers and/or thera-
peutic targets in FUS ALS patients.
We also crossed our data with the transcriptome analysis
from a recently reported murine model (Scekic-Zahirovic
et al., 2016). Among genes commonly upregulated in
both species we noticed TAF15, which is mutated in
some ALS patients (Couthouis et al., 2011). TAF15 is a
member of the FET family of RNA-binding proteins and
is closely related to FUS. Similarly to FUS and TDP-43,
upregulation of WT TAF15 causes neurodegeneration in
Drosophila (Couthouis et al., 2011). Notably, TAF15 levels
were slightly increased in FUS null mice (Kino et al.,
2015; Scekic-Zahirovic et al., 2016), but not in human
MNs with reduced FUS levels (Figure 4D). This discrepancy
might be explained by residual FUS protein in our RNAi
experiment. A shift in TAF15 solubility and its localization
into FUS-positive inclusions has been observed in fronto-
temporal lobar degeneration, but not in ALS (Neumann
et al., 2011). Therefore, it remains unclear whether TAF15
upregulation in FUS mutant MNs contributes to ALS
pathogenesis.
Changes in mRNA levels may be a direct consequence of
the FUS mutation. Despite the fact that specific informa-
tion on FUS-bound transcripts in human MNs is still
missing, FUS CLIP-seq data from human brain cortex are
available (Lagier-Tourenne et al., 2012). Our results suggest
a possible direct effect of FUS mutations on those tran-
scripts that are targeted by FUS on their 30 UTR. Interest-
ingly, levels of several transcripts were altered in the same
direction in homozygous and heterozygous FUSP525L
MNs. The P525L mutation is inherited in an autosomal
dominant way in ALS patients, and homozygous individ-
uals have never been reported. Unexpectedly, in spinal
cord tissue from heterozygous FUS ALS patients a near
absence of nuclear FUS was observed in MNs, suggesting
that both mutant and WT FUS can be sequestered within
cytoplasmic inclusions (Vance et al., 2013). As the nuclear
fraction of FUS in homozygous and heterozygous P525L
cells is, respectively, 80% and 50% (Lenzi et al., 2015),
the homozygous mutant could be regarded as representa-
tive of a more advanced stage of the disease. Mechanisti-
cally, toxic functions of mutant FUS might underlie the
alteration of at least a subset of mRNAs, as suggested by
knockdown experiments.
FUS mutations might also affect gene expression indi-
rectly, for instance by altering miRNA levels. We found
that miR-375 levels were consistently lower in MNs
derived from two independent FUSP525L lines. Bhinge10 Stem Cell Reports j Vol. 9 j 1–13 j November 14, 2017et al. (2016) recently showed that miR-375 is enriched in
human spinal MNs derived from embryonic stem cells.
Interestingly, miR-375 overexpression protected MNs
from DNA damage-induced apoptosis. Mechanistically,
miR-375 may exert this function by targeting p53 (Bhinge
et al., 2016; Liu et al., 2013). We show here that p53 and
other pro-apoptotic miR-375 predicted targets are upregu-
lated in FUS mutant MNs. Notably, spinal MNs of ALS
patients have been shown to display higher levels of p53
protein, which could be involved in apoptosis-mediated
neuronal death (Martin, 2000; Ranganathan and Bowser,
2010).
In FUSP525L MNs we observed 40%–50% reduction in
miR-375 levels. This is strikingly similar to the situation
observed by Bhinge et al. (2016) in SMA MNs, in which
miR-375 levels were reduced to 40%. Therefore, miR-375
dysregulation represents a common feature between
two different MN diseases. While the molecular basis of
miR-375 downregulation in SMA MNs remains currently
unknown, we propose that ALS mutations causing FUS
exclusion from the nucleus impair miR-375 production
via a loss-of-function mechanism.
In addition to p53-induced apoptosis, miR-375 dysregu-
lation might have an impact on other crucial pathways. Its
decrease in FUSP525L MNs is mirrored by an increase of its
target ELAVL4, an RNA-binding protein playing multiple
roles in neural development, function, and degeneration
(Bronicki and Jasmin, 2013). ELAVL4 regulates the stability
and/or localization of several target transcripts.We propose
that FUS, through the miR-375/ELAVL4 axis, is hierar-
chically at the top of a regulatory network with a broader
role in the RNA metabolism of MNs.
In conclusion, transcriptome analysis of isogenic FUSWT
and FUSP525L in-vitro-derived human MNs provided an
insight on target genes and pathways altered by ALS muta-
tions in the cell type primarily affected by the disease.EXPERIMENTAL PROCEDURES
Maintenance and Differentiation of Human iPSCs
Generation and maintenance of iPSC lines is described in Lenzi
et al. (2015). The MN differentiation protocol has been modified
from Hill et al. (2016). In brief, cells were differentiated in N2B27
medium supplemented with 1 mM all-trans retinoic acid (Sigma-
Aldrich) and 1 mM SAG (Merck Millipore) for 12 days in the pres-
ence of 10 mMSB431542 and 100 nMLDN-193189 (both fromMil-
tenyi Biotec) from day 0 to 6, and 5 mM DAPT and 4 mM SU-5402
(both from Sigma-Aldrich) from day 6 to 12. Cells were sorted at
day 12 using a FACSAria III (BD Biosciences) and re-plated on
poly-L-ornithine-coated dishes and laminin- coated dishes (both
from Sigma-Aldrich) in Neural Medium. The Hb9:GFP reporter
was stably integrated in the AAVS1 locus, as described previously
(Wainger et al., 2014).
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Total RNA, extracted with the Quick-RNA MiniPrep (Zymo
Research) and retrotranscribed with SuperScript VILO (Thermo
Fisher Scientific) or miScript II RT (QIAGEN), was analyzed by
real-time qRT-PCR with SYBR Green PowerUP (Thermo Fisher Sci-
entific) or SYBR Green PCR Master Mix (QIAGEN). For miRNAs
384 array, RNA retrotranscribed using the TaqMan MicroRNA RT
Kit was analyzed using the TaqMan Human MicroRNA Array A
(Thermo Fisher Scientific). Primers sequences are reported in
Table S4. Western blot analysis was carried out using anti-p53
(fl-393; Santa Cruz) and anti-GAPDH (sc-32233) antibodies.
RNA-Seq and Bioinformatics Analysis
Total RNA was sequenced on an Illumina HiSeq 2500 sequencing
system using a TruSeq Stranded Total RNA Library Prep Kit with
Ribo-Zero treatment (Illumina) or the TruSeq Small RNA Library
(Illumina) at the Institute of Applied Genomics (Udine, Italy). An
average of about 21 million 125 base pairs long paired-end reads
or 17 million 50 base pairs long single-end reads were produced
for each sample for RNA-seq or small RNA-seq, respectively.
Bioinformatics analysis is described in detail in the Supplemental
Experimental Procedures.
RNA-seq raw data have been deposited at the GEO (GEO:
GSE94888).
Immunostaining
Immunostaining was performed with anti-Islet-1/2 (1:50, 39.4D5;
DSHB) primary antibody and anti-mouse Alexa Fluor 488 (1:250,
Thermo Fisher Scientific) goat secondary antibody. Images were
acquired with an inverted iX73 microscope (Olympus).
FUS Knockdown and miRNA Mimics Transfection
Differentiating FUSWT iPSCs were transfected at 8 and 10 days
with 40 nM anti-FUS siRNAs (SI00070518, QIAGEN) or scramble
control siRNAs (1027281, QIAGEN). FUSP525L iPSCs, induced to
differentiate into MNs for 14 days and seeded on Matrigel-coated
plates, were transfected after 48 hr with 10 nM mirVana miRNA
mimics (miR-375-3p MIMAT0000728; Negative Control No. 1
Cat. 4464058; Thermo Fisher Scientific). RNA was collected for
real-time qRT-PCR analysis after 48 hr.
ACCESSION NUMBERS
The accession number for the RNA sequencing raw data reported
in this paper is GEO: GSE94888.
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Supplemental Information includes Supplemental Experimental
Procedures, five figures, and four tables and can be found with
this article online at https://doi.org/10.1016/j.stemcr.2017.
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Figure S1. MN differentiation and sorting. Related to Figure 1 
(A) Schematic representation of the Hb9::GFP reporter system, inserted in the AAVS1 locus by gene editing with zinc-finger 
nucleases (ZFN). A specific break introduced by ZFN in the AAVS1 locus (arrow) is repaired by homologous 
recombination, introducing a puromycin resistance gene spliced in frame with AAVS1 (SA-PUROr) and a membrane-
localized GFP (M-GFP) coding sequence under the control of the Hb9 promoter. pA indicates cleavage and polyadenylation 
signal site. (B) End-point PCR analysis on the genomic DNA of iPSCs before (FUSWT) or after (FUSWT+Hb9::GFP; 
FUSP525L+Hb9::GFP) transfection with AAVS1 ZFNs and Hb9::GFP reporter system. Primers annealed to the unmodified 
AAVS1 locus (top), to the reporter pA and the AAVS1 locus (outside of the sequence corresponding to the homology arm 
region; middle) or to an unrelated genomic locus as a control, G3BP (bottom). (C) Immunostaining analysis of ISL1/2 and 
TUJ1 markers of cells differentiated for 12 days as in Fig. 1A, dissociated, re-plated on laminin-coated dishes and cultured 
for 2 additional days in Neural Medium. DAPI was used to stain nuclei. Widefield images acquired at a Zeiss Axiovert A1 
microscope with a 40X objective. Scalebar: 20µm. (D) GFP-positive and -negative cells were analyzed by FACS to check 
the purity of the sorted samples. Plot overlay show the purity of isolated populations compared to unsorted sample. (E) 
MDS plot showing clustering of GFP-positive and -negative samples based on log2-transformed CPM values obtained by 
RNA-Seq analysis. (F) Hierarchical clustering and Pearson correlation matrix of GFP-positive and -negative samples based 
on log2-transformed CPM values obtained by RNA-Seq analysis. (G) Heatmap representing RNA-Seq-derived expression 
levels of genes that are differentially expressed between GFP-positive and -negative cells collected after sorting (3 
independent experiments). Plotted values correspond to mean-centered log2-transformed RPKM values. (H) Phase contrast 
images of cells sorted at day 12 for GFP expression and further cultured for 1 (left panel) and 7 (right panel) days on 
laminin-coated dishes. Scalebar: 50µm 
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Figure S2. FUSWT and FUSP525L iPSC generate MNs with comparable efficiency. Related to Figure 2 
(A) Real-time qRT-PCR analysis of the expression of the indicated genes in purified MNs (day12+7). Expression levels in 
FUSP525L, FUSP525L#2 and FUSP525L(ht) are shown as relative to their respective isogenic FUSWT controls, set to a value of 1. 
	 5	
Histogram bars represent the average of at least 3 independent experiments and error bars indicate the standard deviation 
(Student’s t-test; paired; two tails; ***= p<0.001; p>0.05 for all other genes). HB9, ISL1 and CHAT are MN markers. TUJ1 
is a pan-neuronal marker and HPRT is a housekeeping control. (B) MDS plot showing clustering of FUSWT and FUSP525L 
samples based on log2-transformed CPM values obtained by RNA-Seq analysis. (C) Hierarchical clustering and Pearson 
correlation matrix of FUSWT and FUSP525L samples based on log2-transformed CPM values obtained by RNA-Seq analysis. 
(D) Table showing the expression levels (RPKM) of ALS associated genes in RNA-Seq analysis. LogFC indicates log2 fold 
change in FUSWT vs FUSP525L comparison. 
  
	 6	
 
 
 
Figure S3. Characterization of FUSWT#2 and FUSP525L#2 iPSC lines. Related to Figure 2 
(A) Sequencing results from FUSWT#2 and FUSP525L#2 iPSC lines. FUSP525L#2 iPSCs were modified by TALEN-directed 
HDR with the strategy described in (Lenzi et al., 2015). The arrows indicate the targeted nucleotide in codon 525 (C, wild 
type; T, mutant). (B) Immunostaining showing intracellular localization of WT and mutant FUS proteins in iPSCs. Scale 
bar: 10 µm. (C)	 End-point PCR analysis on the genomic DNA of FUSWT#2 and FUSP525L#2 iPSC lines. iPSCs before 
transfection with AAVS1 ZFNs and Hb9::GFP reporter system are used as control (FUSWT). Primers annealed to the 
unmodified AAVS1 locus (top), to the reporter pA and the AAVS1 locus (outside of the sequence corresponding to the 
homology arm region; middle) or to an unrelated genomic locus as a control, G3BP (bottom).	(D) Schematic representation 
of flow cytometry analysis of the fraction of GFP-positive cells at day 12. Histogram bars represent the average of 4 
independent experiments and error bars indicate the standard deviation (Student’s t-test; unpaired; two-tails; n.s.= p>0.05). 
 
 
	 7	 
	 8	
 
 
Figure S4. Bioinformatics analysis of differentially expressed genes in FUSWT and FUSP525L MNs. Related to Figure 3 
(A) Word cloud generated by FIDEA representing GO Biological Process terms enriched in the list of genes that are 
downregulated (left panel) or upregulated (right panel) in FUSP525L MNs. The functional categories are represented with a 
character size proportional to the statistical significance of their enrichment. (B) Top: Venn diagrams showing the overlap 
between downregulated and upregulated genes in the present work and in MNs isolated by laser capture from sALS patients 
(Batra et al., 2016). Bottom: table of commonly upregulated and downregulated genes.  (C) Fraction of TDP-43 bound 
protein-coding genes (identified by Tollervey et al., 2011) which are also differentially expressed genes in FUS mutant 
MNs. A gene was considered to be bound if a TDP-43 iCLIP peak was found within its body; the analysis was repeated 
focusing only on specific pre-mRNA regions (Fisher's exact test; *= p<0.05; ***=p<0.001). (D) Table showing the identity 
of the genes indicated in the Venn diagram of Figure 3E (overlap between differentially expressed genes in the present work 
and in a FUS mutant mouse; Scekic-Zahirovic et al., 2016). 
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Figure S5. Small RNA-Seq analysis. Related to Figure 4 
(A) MDS plot showing clustering of FUSWT and FUSP525L samples based on log2-transformed CPM values obtained by 
small RNA-Seq analysis. (B) The same plot was drawn after removing samples from one differentiation experiment to 
appreciate the pairing of samples originated from the remaining two experiments. (C) Hierarchical clustering and Pearson 
correlation matrix of FUSWT and FUSP525L samples based on log2-transformed CPM values obtained by small RNA-Seq 
analysis. (D) Heatmap representing small RNA-Seq-derived expression levels of miRNAs that are differentially expressed 
between FUSWT and FUSP525L iPSC-derived MNs at day 12+7 (3 independent experiments). Plotted values correspond to 
mean-centered log2-transformed CPM values. (E) Analysis of the expression of selected miRNAs in MNs at day 12+7 by 
real time qRT-PCR. Expression levels in FUSP525L and FUSP525L#2 are shown as relative to their respective isogenic FUSWT 
controls, set to a value of 1. Histogram bars represent the average of at least 3 independent experiments and error bars 
indicate the standard deviation (Student’s t-test; paired; two tails; *= p<0.05; **= p<0.01; n.s.= p>0.05). (F) Analysis of the 
expression of miR-375 in MNs at day 12+7 by real time qRT-PCR. Expression levels in FUSP525L(ht) are shown as relative 
to its isogenic FUSWT control. Histogram bars represent the average of at least 3 independent experiments and error bars 
indicate the standard deviation (Student’s t-test; paired; two tails; n.s.= p>0.05).  
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Groups Total Elements 
   
day 12; day 12+7; small-seq(p-value<0,05) 2 miR-375 
  miR-484 
   
day 12+7; small-seq(p-value<0,05) 3 miR-129-3p 
  miR-125b-5p 
  miR-139-5p 
   
day 12; small-seq(p-value<0,05) 6 miR-504-5p 
  miR-10b-5p 
  miR-149-5p 
  miR-25-3p 
  miR-192-5p 
  miR-185-5p 
   
day 12; day 12+7 47 miR-331 
  miR-106a 
  miR-574-3p 
  miR-93 
  miR-652 
  miR-124a 
  miR-486 
  miR-193b 
  miR-20a 
  miR-532 
  miR-627 
  miR-483-5p 
  miR-200c 
  miR-16 
  miR-216b 
  miR-886-5p 
  miR-26b 
  miR-660 
  miR-140-3p 
  miR-31 
  miR-454 
  miR-30b 
  miR-216a 
  miR-330 
  miR-218 
  let-7g 
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  miR-133a 
  miR-186 
  miR-365 
  miR-92a 
  miR-191 
  miR-184 
  miR-10a 
  miR-26a 
  miR-628-5p 
  miR-125a-5p 
  miR-146b 
  miR-28-3p 
  miR-708 
  miR-886-3p 
  miR-20b 
  miR-296 
  miR-422a 
  miR-425-5p 
  miR-103 
  miR-95 
  miR-598 
 
Table S2. Differentially expressed miRNAs in FUSWT vs FUSP525L MNs (Taqman Array Cards). Related to Figure 4 
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Name Sequence 
AAVS1 FW   CAGGGCCGGTTAATGTGGCT 
AAVS1 HB9 FW   CACTCTCGGCATGGACGAGCTG 
AAVS1 HB9 RV    CCAAAAGGCAGCCTGGTAGACAG 
AAVS1 RV    GGGTTAGACCCAATATCAGG 
ATP1B1 FW AAGCCCACATATCAGGACCGAG 
ATP1B1 RV TGCCTCATAGCTCTTGGGATCAT 
ATP5O FW ACTCGGGTTTGACCTACAGC 
ATP5O RV GGTACTGAAGCATCGCACCT 
B3GAT2 FW TCTTCCAGGAGATGCGAACCAC 
B3GAT2 RV ACAACTTTGCCGTTTTCCACCA 
CDH7 FW  GGAGCCCTGATAGCCATACTCG 
CDH7 RV  GGTTTCTCAGTGCAGCCATGTC 
ChAT FW CTCAGCTACAAGGCCCTGCT 
CHAT RV ACCAGCGTGTCCTGGGTATG 
CRIM1 FW TCGAACCTGCAGCAATCCCTTT 
CRIM1 RV AGAGAACTGGACTTCACAGCGG 
EBF3 FW TCTACGAGGGCCAGGACAAGA 
EBF3 RV GGTCTGAGGGCGTTTCGTTTC 
ELAVL4  FW CAACCCCAGCCAGAAGTCCA 
ELAVL4  RV AGCCTGAACCTCTGAGCCTG 
G3BP1 FW  CCAGGATTTGGAGTGGGAAGGG 
G3BP1 RV   CAGACTGGGGTCATACTCCAAG 
GAPDH FW GGAAGGTGAAGGTCGGAGTC 
GAPDH REV TTACCAGAGTTAAAAGCAGCCC 
GRIN2A FW GGTCAGCCTGAAAACGGGGAA 
GRIN2A RV TGTACCCACTCCCGATGGTCA 
HB9 FW GAGACCCAGGTGAAGATTTG 
HB9 RV CCTTCTGTTTCTCCGCTTCC 
HPRT FW GCCCTGGCGTCGTGATTAGT 
HPRT RV GGCCTCCCATCTCCTTCATCA 
ISL-1 FW TACAAAGTTACCAGCCACC 
ISL-1 RV GGAAGTTGAGAGGACATTGA 
LRFN2 FW CCGGGTGAAGATGTACCAGCT 
LRFN2 RV TGAGTGTCGTGGCTGTGTCAT 
NANOG FW CCAAATTCTCCTGCCAGTGAC 
NANOG RV CACGTGGTTTCCAAACAAGAAA 
NNAT FW TGCTCATCATCGGCTGGTACA 
NNAT RV ACACCGTGTATGCCAGCTTCT 
NRN1 FW  GGCTTTTCGGACTGTTTGCTCA 
NRN1 RV  ATCCTCCCAGTATGTGCACACG 
NXPH2 FW TCCCCTGCGCCTGTTTGTTAAA 
NXPH2 RV CCAATGGCTCCTGAATCTCCGT 
PAX FW ATGTGTGAGTAAAATTCTGGGCA 
PAX RV GCTTACAACTTCTGGAGTCGCTA 
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PHLDA1 FW CAGAGGGCAAGGAGATCGACTT 
PHLDA1 RV GGCCTGACGATTCTTGTACTGC 
SHISA6 FW CGAGAACAAGTACGACCCGGA 
SHISA6 RV AGCCCTGTGGATGTTCATCTCC 
SLC17A8 FW ACGCCGTGGGAGATTCTTTGG 
SLC17A8 RV TGATGTAACGCTTGGGGAGGC 
TAF15 FW GGGTCACAGGGAGGAGGTAGA 
TAF15 RV CCATAATCCCTGTGACCACCAAAA 
TAF7 FW  GGGCGTCATGGAATCGTCAGA 
TAF7 RV TCAAGCTTTCCATAACACAGGGCA 
TP53 FW TGGCCATCTACAAGCAGTCACA 
TP53 RV CGGATAAGATGCTGAGGAGGGG 
TP53I3 FW CTCACCGCCTTCCAGCTGTT 
TP53I3 RV CGGGTGAGTTGGATAGCAGCT 
TSPYL5 FW GGCCCAATCCCTTGCAGTTCT 
TSPYL5 RV TGCTTTCCTGGACCTTGCCTG 
TUJ1 FW CCCGGAACCATGGACAGTGT 
TUJ1 RV TGACCCTTGGCCCAGTTGTT 
Hs_SNORD25_11 miScript Primer Assay (SNORD25 small nucleolar RNA, C/D box 25) 
Hs_miR-125b_1 miScript Primer Assay MIMAT0000423: 5'UCCCUGAGACCCUAACUUGUGA 
Hs_miR-10b_3 miScript Primer Assay MIMAT0000254: 5'UACCCUGUAGAACCGAAUUUGUG 
Hs_miR-184_1 miScript Primer Assay MIMAT0000454: 5'UGGACGGAGAACUGAUAAGGGU 
Hs_miR-186_1 miScript Primer Assay MIMAT0000456: 5'CAAAGAAUUCUCCUUUUGGGCU 
Hs_miR-218_1 miScript Primer Assay MIMAT0000275: 5'UUGUGCUUGAUCUAACCAUGU 
Hs_miR-302a_2 miScript Primer Assay MIMAT0000684: 5'UAAGUGCUUCCAUGUUUUGGUGA 
Hs_miR-367_2 miScript Primer Assay MIMAT0000719: 5'AAUUGCACUUUAGCAAUGGUGA 
Hs_miR-375_2 miScript Primer Assay MIMAT0000728: 5'UUUGUUCGUUCGGCUCGCGUGA 
Hs_miR-484_1 miScript Primer Assay MIMAT0002174: 5'UCAGGCUCAGUCCCCUCCCGAU 
 
 
Table S4. Oligonucleotides and probes used in this study. Related to Experimental Procedures  
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
Maintenance and differentiation of human iPSCs 
Generation and validation of iPSC lines is described in Lenzi et al. (Lenzi et al., 2015). All iPSC lines were maintained in 
Nutristem-XF (Biological Industries, Kibbutz Beit-Haemek, Israel) in plates coated with hESC-qualified Matrigel (Corning 
Inc., Corning, NY) and passaged every 4-5 days with 1 mg/ml Dispase (Thermo Fisher Scientific, Waltham, MA). MN 
differentiation protocol has been modified from Hill et al. (Hill et al., 2016). iPSCs were dissociated to single cells with 
Accutase (Thermo Fisher Scientific) and counted. 9x105 cells were seeded onto each well of a 6-well Matrigel-coated plate 
in Nutristem-XF supplemented with 10 µM ROCK-inhibitor (Y-27632, Sigma-Aldrich, St. Louis, MO) to enhance survival 
upon dissociation. The ROCK-inhibitor was withdrawn the next day. After two days (day 0), cells reached confluence and 
medium was switched to N2B27 Medium, composed of 50% DMEM/F12 (Sigma-Aldrich) and 50% Neurobasal (Thermo 
Fisher Scientific) supplemented with 1X N2 and 1X B27, 1X Glutamax, 1X MEM Non-Essential Aminoacids (all from 
Thermo Fisher Scientific) and 100 U/ml Penicillin + 100 µg/ml Streptomycin (Sigma Aldrich). 10 µM SB431542 (Miltenyi 
Biotec, Bergisch Gladbach, Germany) and 100 nM LDN-193189 (Miltenyi Biotec) were added to the medium from day 0 to 
6, while 5 µM DAPT (Sigma-Aldrich) and 4 µM SU-5402 (Sigma Aldrich) were added from day 6 to 12. 1 µM all-trans 
Retinoic Acid (Sigma-Aldrich) and 1 µM SAG (Merck Millipore, Billerica, MA) were added to the medium from day 0 to 
12. Medium was replaced daily during the course of differentiation.  
Cells were dissociated at day 12 with the Papain Dissociation System (Worthington Biochemical Corp., Lakewood, NJ) and 
single cell suspensions were prepared for isolation in sorting buffer (PBS without Ca2+/Mg2+; 2.5% Horse Serum; 0.4% 
Glucose; DNAseI; all from Sigma-Aldrich) containing 1X B27 Supplement (Thermo Fisher Scientific). 
After sorting, cells were re-plated on poly-L-ornithine (Sigma-Aldrich) and natural mouse laminin (Sigma-Aldrich) coated 
dishes in Neural Medium (N2B27 Medium supplemented with 20 ng/ml BDNF, 10 ng/ml GDNF, 10ng/ml CNTF, all from 
Peprotech, London, UK; 200 ng/ml L-ascorbic acid, Sigma-Aldrich; and ROCK-inhibitor for the first 24 hours). Neural 
Medium without ROCK-inhibitor was replaced every 3 days until collection of cells. The Hb9::GFP reporter, kindly 
provided by Dr. Kevin Eggan, was stably integrated in the AAVS1 locus by targeted Zinc Finger Nucleases (ZFNs) as 
previously described (Wainger et al., 2014). Briefly, AAVS1 ZFNs and the template construct containing the reporter and a 
puromycin resistance gene were co-transfected in iPSCs using the Neon Transfection System (Thermo Fisher Scientific) as 
described (Lenzi et al., 2015). After 48 hours, transfected cells were selected with 0.5 µg/ml puromycin and then clonally 
expanded. 
 
Isolation of differentiated MNs by fluorescent-activated cell sorting (FACS) 
Human MNs were sorted based on GFP expression from the Hb9::GFP reporter using a FACSAriaIII (BD Biosciences, San 
Jose, CA) equipped with a 488nm laser and FACSDiva software (BD Biosciences version 6.1.3). Data were analyzed using 
the FlowJo software (Tree Star, Ashland, OR). Briefly, cells first gated based on forward and side scatter area (FSC-A and 
SSC-A) plot were then detected in the green fluorescence channel for GFP expression (530/50nm filter) and collected as 
negative (GFP-) and positive cells (GFP+). To reduce stress for the neurons, cells were isolated in gentle conditions using a 
ceramic nozzle of size 100µm, a low sheath pressure of 19.84 pound-force per square inch (psi) that maintains the sample 
pressure at 18.96 psi and an acquisition rate of 3000 events/s. According to the different use, cells were collected in 5 and/or 
15 ml polystyrene or polypropylene tubes. Following isolation, an aliquot of each tube of the sorted cells was evaluated for 
purity resulting in an enrichment  >98-99% for each sample. 
To check the course of differentiation, an aliquot of cells was acquired starting from day 6 every 2 days at the flow 
cytometer LSRFortessa  (BD Biosciences), equipped with a 488nm laser, to evaluate GFP expression levels. 
 
Real-time qRT-PCR and western blot analysis 
Total RNA was extracted with the Quick RNA MiniPrep (Zymo Research, Irvine, CA) and retrotranscribed with 
SuperScript VILO (Thermo Fisher Scientific) or miScript II RT (Qiagen, Venlo, Netherlands). Real-time qRT-PCR analysis 
was performed with SYBR Green Power-UP (Thermo Fisher Scientific) or SYBR Green PCR Master Mix (Qiagen) in a 
ViiA7 Real Time PCR System (Thermo Fisher Scientific) and calculations performed with the delta delta Ct method. The 
internal control for mRNA analysis is the housekeeping gene ATP5O (ATP synthase, H+ transporting, mitochondrial F1 
complex, O subunit). For miRNA analysis internal control is U25 (SNORD_25). Primers sequences are reported in Table 
S4. 
Western blot analysis of p53 protein levels was carried out with NuPAGE 4-12% Bis-Tris gels  (Thermo Fisher Scientific) 
in MOPS-SDS buffer, using anti-p53 (fl-393; Santa Cruz, Dallas, TX) and, as a loading control, anti-GAPDH (sc-32233; 
Santa Cruz) antibodies. Images were acquired with the Chemidoc MP (BioRad, Hercules, CA).  
 
miRNAs 384 array 
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200ng total RNA from MNs was retrotranscribed using the TaqMan MicroRNA RT Kit (Thermo Fisher Scientific). The 
real-time detection of the miRNA levels was performed using the TaqMan® Human MicroRNA Array A (Thermo Fisher 
Scientific), according to manufacturer's instructions, in a ViiA7 Real Time PCR System (Thermo Fisher Scientific). The 
values obtained were normalized for snoRNA-U44. 
 
RNA sequencing and bioinformatics analysis 
Total RNA was extracted from iPSC-derived MNs (GFP-negative and positive with a FUSWT genotype, day12; FUSWT and 
FUSP525L, day 12+7) and sequenced on a Illumina Hiseq 2500 Sequencing system using TruSeq Stranded Total RNA 
Library Prep Kit with Ribo-Zero treatment (Illumina, San Diego, CA) at the Institute of Applied Genomics (IGA; Udine, 
Italy). An average of about 21 million 125 base pairs long paired-end reads were produced for each sample. 
RNA-Seq reads were initially trimmed using the Trimmomatic software (Bolger et al., 2014) to remove adapter sequences 
and poor quality bases; the minimum read length after trimming was set to 18. After that, Bowtie 2 (Langmead and 
Salzberg, 2012) was used to align reads to human rRNA sequences; reads mapping to these sequences were filtered out. In 
order to calculate the distribution of the inner distance between mate pairs, reads were aligned to a non-redundant set of 
human RNA sequences derived from Ensembl 77 gene annotation (Flicek et al., 2014) using BWA software (H. Li and 
Durbin, 2010); this mapper was chosen because of its ability to automatically infer the insert size. Mean and variance of 
inner distance distribution were estimated from aligned read pairs whose inner distance was within interval [Q1-2(Q3-
Q1),Q3+2(Q3-Q1)] (Q1=first quartile, Q3=third quartile), the same as used by BWA to estimate the insert size. TopHat2 
(Kim et al., 2013) was employed to align reads to GRCh38 human genome and Ensembl transcriptome using parameters -i 
50 -r -32 --mate-std-dev  58 --library-type fr-firststrand. Read counts for Ensembl 77 human genes were calculated using 
htseq-count software (Anders et al., 2015), specifying the intersection-strict option. Number of reads and mapping statistics 
are reported in Table S1. edgeR software (Robinson et al., 2010) was used to find differentially expressed genes in GFP-
positive vs GFP-negative and FUSWT vs FUSP525L comparisons. In both cases, TMM normalization was applied to read 
counts after filtering genes with a CPM (Count Per Million) value less than 1 in at least three (in GFP-positive vs GFP-
negative comparison) or four (in FUSWT vs FUSP525L comparisons) samples. MDS plots and Pearson correlation-based 
sample correlation matrices were drawn based on log2-transformed normalized read counts. For FUSWT vs FUSP525L 
comparison, samples originating from the same differentiation experiment showed some degree of pairing and this was 
taken into account when performing differential expression analysis. An additive model was fitted to adjust for baseline 
differences between the three independent differentiation experiments: design <- model.matrix (~ experiment + condition). 
Model fitting and testing was performed using glmFIT and glmLRT functions. Heatmaps of differentially expressed genes 
were plotted based on mean-centered log2-transformed RPKM values, calculated using rpkm function.  
Functional enrichment analysis of genes deregulated upon FUS mutation was performed by providing the list of 
differentially expressed protein-coding genes to FIDEA Web Server (D'Andrea et al., 2013), using the list of protein-coding 
genes that passed the CPM-based filter as background. GSEA analysis was performed using GSEA software (Hill et al., 
2016; Subramanian et al., 2005), with the permutation type parameter set to gene set. 
Cufflinks software (Trapnell et al., 2010) was employed to evaluate transcript-level expression in FUSWT and FUSP525L 
conditions, using parameters --compatible-hits-norm --max-frag-multihits 1. Transcripts with FPKM > 0.1 and belonging to 
genes with FPKM > 0.5 in at least three samples were flagged as expressed. 
 
CLIP-Seq data reanalysis 
Raw reads from FUS HITS-CLIP experiment conducted by Lagier-Tourenne and coworkers (Lagier-Tourenne et al., 2012) 
on human brain cortex were downloaded from GEO. First, adapter and quality trimming of reads was performed using 
Trimmomatic; Cutadapt was then used to remove all the adapter sequences that were not trimmed in the first phase. 
Trimmed reads were aligned to GRCh38 using Bowtie (Langmead et al., 2009) with parameters -a -m 1 --best --strata. 
Duplicate reads, which could represent PCR artifacts, were removed using MarkDuplicates from Picard 
(picard.sourceforge.net/command-line-overview.shtml). Tools from the Pyicoteo suite (Althammer et al., 2011) were used 
to call CLIP-Seq peaks. First, all reads were extended to a length of 36 nucleotides using the pyicos extend tool. Then, 
CLIP-Seq peak calling was performed using the pyicoclip tool. Ensembl 77 GTF file was supplied to generate exploratory 
regions, using the option --region-magic genebody. Only peaks with p-value < 0.001 were retained. Colocalization of FUS 
CLIP-Seq peaks with different regions of expressed protein-coding transcripts was evaluated as follows: each protein-
coding locus was divided into coding sequence (CDS), 5' UTR, 3'UTR, proximal and distal intron regions (the latter being 
defined as the intronic regions which are more than 500 bp far from the nearest exon-intron boundary), giving priority to 
CDS over the other regions; then each peak was assigned a region based on the position of the peak summit using the 
BEDTools software suite (http://bedtools.readthedocs.io/). Enrichment of peaks in each region relative to region size was 
computed as described (Kapeli et al., 2016). For the analysis of differential FUS binding between deregulated and non-
deregulated genes, bound genes were defined as those hosting at least one FUS CLIP-Seq peak, either within the entire gene 
body or in a specific pre-mRNA region. 
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TDP-43 binding sites obtained by iCLIP in human brain (Tollervey et al., 2011) were downloaded from starBase v2.0 Web 
Server (J.-H. Li et al., 2014). hg19 coordinates were converted to GRCh38 coordinates using the liftOver tool (The UCSC 
Genome Browser Database: update 2006). The center of each iCLIP cluster was used to assign it to a pre-mRNA region. 
 
Small RNA-Seq 
Total RNA was extracted from iPSC-derived MNs (FUSWT and FUSP525L, day 12+7) and sequenced on a Illumina Hiseq 
2500 Sequencing system using TruSeq Small RNA Library (Illumina) at the Institute of Applied Genomics (IGA; Udine, 
Italy). An average of about 17 million 50 base pairs long single-end reads were produced for each sample. mirPRo software 
(Shi et al., 2015; Subramanian et al., 2005) was used to remove adapter sequences, map reads to human pre-miRNA 
sequences downloaded from mirBase v21 (Kozomara and Griffiths-Jones, 2014) using NovoAlign (H. Li and Homer, 
2010), and calculate read counts for mature miRNAs. Number of reads and mapping statistics are reported in Table S1. 
Starting from the raw counts, sample clustering and differential expression of mature miRNAs were performed using the 
same procedure adopted for FUSWT vs FUSP525L comparison. Samples originating from the same differentiation batch were 
mildly correlated, so we opted for a paired design when performing differential expression analysis. The heatmap of 
deregulated mature miRNAs was plotted based on mean-centered log2-transformed CPM values.  
 
Immunostaining 
MNs were re-plated on matrigel-coated dishes and cultured for additional 3 days (day12+3), then were fixed in 2% 
paraformaldehyde for 15 minutes at room temperature and washed twice with PBS. Fixed cells were then permeabilized 
with PBS containing 1% BSA and 0.2% Triton X-100 and incubated 1h with primary antibody anti-Islet-1/2 (1:50, 39.4D5 
DSHB, Iowa City, Iowa) and TUJ1 (1:200; T2200; Sigma-Aldrich) at room temperature. The secondary antibodies are goat 
anti-mouse Alexa Fluor 488 (1:250, Thermo Fisher Scientific) and goat anti-rabbit Cy3 (1:250, Jackson ImmunoResearch, 
Suffolk, UK). DAPI (Sigma-Aldrich) was used to stain nuclei. Fluorescent images were acquired using a 20X LWD 
objective mounted on an inverted iX73 microscope (both Olympus, Tokyo, Japan) with Lumencor Spectra X LED 
illumination, a CoolSNAP MYO CCD camera (Photometrics, Tucson, AZ), and MetaMorph software (Molecular Devices, 
Sunnyvale, CA).  
iPSCs were fixed in 4% paraformaldehyde for 15 minutes at room temperature and washed twice with PBS. Fixed cells 
were then permeabilized with PBS containing 1% BSA and 0.2% Triton X-100 and incubated with the primary antibody 
anti-FUS/TLS (4H11) (1:100; SC-47711; Santa Cruz Biotechnologies) for 1 hour at room temperature. The secondary 
antibody is goat anti-mouse Alexa Fluor 488 (1:250, Thermo Fisher Scientific). DAPI (Sigma-Aldrich) was used to stain 
nuclei. Confocal images were acquired at the Olympus iX83 FluoView1200 laser scanning confocal microscope using a 
UPLSAPO60xO, NA 1,35 oil objective. The standard setting for DAPI and Alexa Fluor 488 emission and 405nm and 
473nm laser for excitation were used. Images were acquired at 800x800 pixel, 4x zoom, line scan sequential mode. 
 
FUS knockdown 
For FUS knockdown experiments, FUSWT iPSCs were induced to differentiate and transfected at 8 and 10 days with 40 nM 
anti-FUS siRNAs (Hs_FUS_4 FlexiTube siRNA, SI00070518, Qiagen) or scramble control siRNAs (AllStars Neg. Control 
414 siRNA, 1027281, Qiagen) using Lipofectamine RNAi-Max (Thermo Fisher Scientific), according to manufacturer’s 
instructions.  
 
miRNA mimics transfection 
FUSP525L iPSCs were induced to differentiate into MNs for 14 days. After dissociation with Accutase (Thermo Fisher 
Scientific), cells were seeded on Matrigel-coated plates and then transfected after 48 hours with 10nM mirVana miRNA 
mimics (Thermo Fisher Scientific) (microRNA-375-3p MIMAT0000728; miRNA Mimic Negative Control#1 Cat. 
4464058) using Lipofectamine 2000 (Thermo Fisher Scientific), according to manufacturer’s instructions. RNA was 
collected for real-time qRT-PCR analysis after 48 hours. 
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